A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

NCT05471856 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: BI 1703880
DRUG: Ezabenlimab

Sponsor

Boehringer Ingelheim